Heart failure & cardiomyopathies
Intravenous Iron and SGLT2 Inhibitors in Iron-Deficient Patients with Heart Failure and Reduced Ejection Fraction
Authors' conclusion
In the IRONMAN trial, there was a trend to a greater increase in haemoglobin with ferric derisomaltose in iron-deficient patients taking an SGLT2 inhibitor at baseline, as compared with those not taking one.
Study context
- Population
- Patients with HF, left ventricular ejection fraction (LVEF) ≤ 45% and iron deficiency (transferrin saturation <20% or ferritin <100 μg/L)29 (2.6%) on SGLT2 inhibitor
- Participants
- 1,137 patients
- Comparison
- IV ferric derisomaltose vs usual care, by baseline SGLT2 inhibitor use
- Primary endpoint
- Change in haemoglobin from baseline, by baseline SGLT2 inhibitor use
- Follow-up
- 4 weeks
Methodological detailspost hoc exploratory analysis, open label
- Post hoc exploratory analysis
- Open label
Primary result
As reported in the abstract
Change in haemoglobin from baseline
Ferric derisomaltose (SGLT2 inhibitor)
1.3
mean · SD 1.2 · g/dL
Usual care (SGLT2 inhibitor)
0.1
mean · SD 0.7 · g/dL
Ferric derisomaltose (no SGLT2 inhibitor)
0.6
mean · SD 0.9 · g/dL
Usual care (no SGLT2 inhibitor)
0.1
mean · SD 0.8 · g/dL
Ferric derisomaltose vs Usual careBetween-group difference, g/dL (95% CI)
SGLT2 inhibitor at baseline
1.0(0.1–1.8)
No SGLT2 inhibitor
0.4(0.3–1.6)
Safety
Polycythaemia (Hb >16.5 g/dL [men] or >16 g/dL [women]) in patients on SGLT2 inhibitor · during follow-up
- No patient on SGLT2 inhibitor at baseline developed polycythaemia
Original publication
Intravenous Iron and SGLT2 Inhibitors in Iron-Deficient Patients with Heart Failure and Reduced Ejection Fraction. ESC Heart Fail. Published 28 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →